Standardisation of Indian medical devices process started!!

Soon, Our country designed medical devices will come with the ‘Indian standard’ benchmarked and nearly 1,000 products are currently being benchmarked.

VK Paul, NITI Aayog member said that the process of the standardization is expected to be finished in the next two months at a conference. He also addressed that our country didn’t have any Indian standards developed for the standardization of the medical devices. But from now the process of standardization has been initiated and, about 1,000 products’ are being standardized, and the deadline for that process is about two months. He also said that from old to new devices, many of them will carry Indian standardization from the Bureau of Indian Standards (BIS).

The Bureau of Indian Standards(BIS) is the National Standards Body of India, established in 1986. It is working under the aegis of the Ministry of Consumer Affairs, Food & Public Distribution, Government of India.

In 2015, the Indian medical device market was around Rs.25,000 crore in 2015 and is expected to double itself to over Rs.50,000 crore by 2020. It is also expected that the Indian pharmaceutical growth will outperform. Due to the lack of proper regulatory systems, the success of the domestic manufacturers in the pharma sector hinders and now with the creation of ecosystems will help a country to turn into a medical devices hub.

Indian domestic market is dominant in producing high-volume and a low-cost segment of medical products like disposable syringes and gloves, which contribute to a large chunk of the country’s medical device exports. For low-volume, high-tech equipment manufacturing, the Indian market has a different story.

To provide quality assurance and standards, the government decided to bring ‘Indian standard’ for medical devices. The government assumes that MNCs are alleged to be using their resources to modify the International Organisation for Standardisation (ISO) definition to gain a strategic competitive advantage in the market.

For an example, Domestic producers showed anger on a recent proposal to revise the ISO 7886-3 Standard of auto-disable (AD) syringes for fixed-dose immunisation. This proposal only favors a few multinational corporations and put Indian producers and other developing countries in jeopardy.

Related Posts

Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

HC denies bail to pharma company owner for manufacturing spurious drugs

Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gujrat leads pharma sector with record 183 new plants

Gujrat leads pharma sector with record 183 new plants

Doctor not liable for prescribing costly drug: HC

Doctor not liable for prescribing costly drug: HC

878 Tramadol capsules being smuggled in Scorpio seized, three arrested

878 Tramadol capsules being smuggled in Scorpio seized, three arrested

Doctor not criminally liable for prescribing costly drug: Orissa High Court

Doctor not criminally liable for prescribing costly drug: Orissa High Court